CA2941346C - Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis - Google Patents

Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis Download PDF

Info

Publication number
CA2941346C
CA2941346C CA2941346A CA2941346A CA2941346C CA 2941346 C CA2941346 C CA 2941346C CA 2941346 A CA2941346 A CA 2941346A CA 2941346 A CA2941346 A CA 2941346A CA 2941346 C CA2941346 C CA 2941346C
Authority
CA
Canada
Prior art keywords
zoledronic acid
administration
steroid
osteoarthritis
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2941346A
Other languages
English (en)
French (fr)
Other versions
CA2941346A1 (en
Inventor
Ketan Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Levolta Pharmaceuticals Inc
Original Assignee
Levolta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levolta Pharmaceuticals Inc filed Critical Levolta Pharmaceuticals Inc
Publication of CA2941346A1 publication Critical patent/CA2941346A1/en
Application granted granted Critical
Publication of CA2941346C publication Critical patent/CA2941346C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CA2941346A 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis Active CA2941346C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US13/791,685 2013-03-08
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
CA2941346A1 CA2941346A1 (en) 2014-09-12
CA2941346C true CA2941346C (en) 2020-03-10

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2941346A Active CA2941346C (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Country Status (12)

Country Link
US (1) US9012432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2964209B1 (cg-RX-API-DMAC10.html)
JP (2) JP6839491B2 (cg-RX-API-DMAC10.html)
KR (1) KR102253394B1 (cg-RX-API-DMAC10.html)
CN (1) CN105324113B (cg-RX-API-DMAC10.html)
AU (1) AU2014225373B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015021503B1 (cg-RX-API-DMAC10.html)
CA (1) CA2941346C (cg-RX-API-DMAC10.html)
EA (1) EA032067B1 (cg-RX-API-DMAC10.html)
ES (1) ES2904365T3 (cg-RX-API-DMAC10.html)
MX (1) MX377447B (cg-RX-API-DMAC10.html)
WO (1) WO2014138712A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3428178A4 (en) 2016-03-09 2019-09-04 Bio Pep Co., Ltd. PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
WO2001047559A1 (fr) * 1999-12-27 2001-07-05 Teikoku Seiyaku Co., Ltd Pastilles a usage externe
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1402066A4 (en) * 2001-06-08 2008-10-22 Ortho Mcneil Pharm Inc PAIN TREATMENT WITH HYPERPOLARIZATION ACTIVATED CHANNELS CONTROLLED BY CYCLIC NUCLEOTIDE AS ATTACK POINT
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
PT2049123E (pt) * 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
US20100158905A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
EP2427160A4 (en) * 2009-05-04 2012-12-19 Zars Pharma Inc METHOD FOR TREATING PAIN RELATED TO NEUROMAS, NERVE CLAIMS AND OTHER SUFFERING PAINS
US8946199B2 (en) 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion

Also Published As

Publication number Publication date
JP6839491B2 (ja) 2021-03-17
MX377447B (es) 2025-03-10
EP2964209A1 (en) 2016-01-13
EA032067B1 (ru) 2019-04-30
CA2941346A1 (en) 2014-09-12
BR112015021503B1 (pt) 2022-09-06
EA201591638A1 (ru) 2016-02-29
ES2904365T3 (es) 2022-04-04
EP2964209B1 (en) 2021-10-27
US9012432B2 (en) 2015-04-21
KR20150125001A (ko) 2015-11-06
MX2015011671A (es) 2016-05-12
CN105324113B (zh) 2018-07-03
EP2964209A4 (en) 2016-08-03
AU2014225373A1 (en) 2015-10-22
AU2014225373B2 (en) 2018-07-05
CN105324113A (zh) 2016-02-10
JP2019104762A (ja) 2019-06-27
BR112015021503A2 (en) 2018-05-15
KR102253394B1 (ko) 2021-05-20
JP2016510765A (ja) 2016-04-11
US20140256681A1 (en) 2014-09-11
WO2014138712A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US9737553B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
EP2964209B1 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
Patel et al. The incidence of acute anterior uveitis after intravenous zoledronate
MX2012014428A (es) Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
US20110263537A1 (en) Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion
Dickinson et al. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment
US20210393630A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
JP6656484B2 (ja) 放射性抗腫瘍剤
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
Tomlinson Multiple myeloma: Updated approach to management in 2018
HK1217918A1 (zh) 用於治疗何杰金氏淋巴瘤的4-氰基-n-(2-(4，4-二甲基环己-1-烯-1-基)-6-(2，2，6，6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-酰胺
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
US20250177352A1 (en) Combination treatment for cancer
JP2022508692A (ja) 転移性前立腺がんを処置するための併用療法
Hossain et al. Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women
Gilcher INT-009 Pharmacokinetics of linezolid and meropenem in intensive care unit patients receiving continuous renal replacement therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420